Can risk-adapted treatment recommendations replace the 'one size fits all' approach for early-stage thyroid cancer patients?
Tuttle
R Michael
RM
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Fagin
James A
JA
D003131:Combined Modality Therapy; D006801:Humans; D009367:Neoplasm Staging; D012307:Risk Factors; D013964:Thyroid Neoplasms / Q000473:pathology / Q000628:therapy*